Patients with PF-ILD, excluding scleroderma
Conditions
Interventions
After onset of nintedanib-associated diarrhea, nintedanib dose was reduced (nintedanib 150 mg twice a day in the morning and evening is reduced to 100 mg twice a day).
After onset of nintedanib-associ
Sponsors
Shinmatsudo central general Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with PF-ILD, excluding scleroderma 20 to 80 years old at the time consent is obtained Any previous treatment is included Written informed consent is obtained
Exclusion criteria
Exclusion criteria: Those who consume yogurt (including beverages) within 1 week prior to the start of nintedanib Those who already taking MIYA BM or Biofermin before starting nintedanib Patients allergic to digestive medications Those who are deemed by the attending physician to be ineligible for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in diarrhea index in patients with nintedanib-associated diarrhea in the nintedanib dose reduction group and MiyaBM addition group | — |
Countries
Japan
Contacts
Public ContactKazuko Tanaka
Shinmatsudo central general Hospital Pulmonary medicine
Outcome results
None listed